Gilead Submits NDA for Bulevirtide, First Potential HDV Treatment, Backed by Phase 3 MYR301 Data
Gilead Sciences submitted an NDA to the FDA for bulevirtide 10 mg to treat chronic hepatitis delta virus, supported by Phase 3 MYR301 data.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Gilead Sciences